netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Eye Drops Could Clear Up Cataracts Using Newly Identified Chemical

Dogs develop age-related cataracts just like people.

RPB-supported researchers have partially reversed cataracts in dogs using eye drops and injections of a naturally occurring steroid in the human body. The discovery is pointing to an eye drop treatment for cataracts for people, and the impact will be global.

Cataracts are the leading cause of blindness worldwide, accounting for more than half of all cases. They most commonly occur over time, with age, when the transparent, tight protein structure of the human lens is disrupted, usually by protein aggregation caused by oxidative stress.

The National Eye Institute estimates that by age 80, more than half of all Americans either have a cataract or have had surgery to remove one.

The only treatment now available for cataracts is surgical removal of the natural lens and replacement with a plastic lens. While the surgery has very high success rates, in developed countries it contributes to higher healthcare costs. As populations age, estimates indicate that cataract surgeries will double in the next 20 years. Because cataract surgery emerges as an option later in life, delaying the development of the disease by as little as ten years might eliminate the need for nearly half of those surgeries.

Enter lanosterol, which the human body produces as a precursor to the creation of cholesterol. RPB-supported scientists identified a genetic mutation that interfered with the production of lanosterol in the cases of three children who had a severe, inherited cataract condition. In lab tests, lanosterol was shown to dissolve aggregated lens proteins.

"While we have yet to determine precisely how lanosterol is working, we are gratified that the treatment is working," said RPB resesarcher Dr. Kang Zhang, professor of ophthalmology and chief of ophthalmic genetics at UC San Diego.

Before testing can begin in humans, researchers will check the toxicity of lanosterol, then create an eye drop version of the drug, hopefully within a year.

Read the press release

 

 

Related News: Cataract, Top Story

David F. Weeks

In Memoriam: David F. Weeks

The RPB Chairman Emeritus made an incredible impact on the vision research field, from his efforts to initiate support for the creation of the National Eye Institute to his decades-long leadership of RPB.

Read More

 
rpb logo

Research to Prevent Blindness and American Academy of Ophthalmology Award Grants for Big Data Research to Improve Patient Care

Award recipients to use IRIS Registry database to improve diagnosis and treatment of eye disease

Read More

 
RPB logo

Research to Prevent Blindness and Association of University Professors of Ophthalmology Announce 2022 Recipient of RPB David F. Weeks Award for Outstanding Vision Research

Donald Zack, MD, PhD, is recognized for ground-breaking contributions to the field of vision research.

Read More

 
William vanden Heuvel

In Memoriam: William J. vanden Heuvel

The RPB Board Member, who was a U.S. Ambassador, lawyer, and champion of human rights, worked tirelessly for causes he believed in.

Read More

 
Photo of eye
Watch The Video

RPB HOSTS VIRTUAL EVENT ON LOW VISION

The online event featured RPB grantees and is now available to view on demand.

Read More

 
RPB logo

Research to Prevent Blindness and The Glaucoma Foundation Offer Critical Funding for Early-Career Vision Scientists

The Career Advancement Awards—one focused specifically on glaucoma research—support novel science related to eye diseases by up-and-coming researchers.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.